Airway microbiome, nasal microRNA, and age 6-year asthma phenotypes in the MARC-35 cohort.

September 18, 2018

Airway microbiome, nasal microRNA, and age 6-year asthma phenotypes in the MARC-35 cohort.

  • Clinical Trial Information

    Trial Contact: Tilme, Linda; Beltran, Yajira

    Trial Phone: 321.843.5278 ; 321.841.7619

  • IRB No: 18.037.03

    Protocol Abbrev: MARC35-6 Year

    Principal Investigator: Federico Ricardo Laham, MD

    Age Group: Pediatric

    Secondary Protocol No: MARC35-6 Year

    Treatment: Exam and speciman collection

  • Objective

    Aim 1. To investigate the relation of the airway microbiome to risk of childhood asthma among infants with severe bronchiolitis (MARC-35).

    Aim 2. To investigate the relation of longitudinal patterns of the airway microbiome (e.g., infancy, age 3y, and age 6y) to the risk of childhood asthma in the MARC-35 and MARC-43 cohorts combined. MARC-43 is a separate cohort of children enrolled as healthy infants; it is funded by UG3OD023253 and covered by a separate IRB application at sites involved.

    Aim 3. To identify nasal airway microRNAs that are prospectively associated with asthma at age 6 years.

    Aim 4. To compare asthma cases vs non-cases on downstream NFκB signaling mediators and outcomes associated with nasal airway microRNAs.

    Aim 5. To derive asthma endotypes at age 6 years. By integrating microRNA expression, NFκB signaling mediators and outcomes, and asthma phenotyping data from the age 6-year examination, we will determine asthma endotypes with the use of an innovative systems-based approach.

  • Key Eligibility

    ▪ Previously enrolled in MARC-35 42-Month

    ▪ Age 6.0 (age 72 months) to 7.9 years (age 95 months) of age at the time of the inperson exam

    ▪ Ability of the parent/legal guardian to give informed consent